Eli Lilly says other antibody trials ongoing after pause in one study
Lilly said it is reviewing safety data that caused federal researchers to pause a trial of the company’s COVID-19 antibody treatment in hospitalized patients. Other trials using lower doses of the drug outside the hospital will continue.